FDA puts Bright Minds drug on partial hold, stock tanks

Bright Minds Biosciences' stock plummeted 57.6% to $23.31 in early trading after the FDA placed its investigational new drug application for BMB-101 on a partial clinical hold. The FDA's main concerns revolved around observed toxicity in mice and insufficient data on drug's pharmacokinetics and toxicity in juveniles, which are crucial for the planned Phase 2 clinical trial.

Bright Minds claimed the hold only affects the U.S. Developmental and Epileptic Encephalopathies (DEE) trial, unaffected by their other ongoing clinical programs. However, their argument, supported by their own toxicology reports and opinions from independent experts, didn't seem to ease investor fears. The FDA will deliver its full Partial Clinical Hold Letter within 30 days, leaving investors uncertain about the timing and conditions for lifting the hold.

The sudden stock reaction was fueled by the pre-market drop of around 45%, as Nasdaq paused trading for DRUG at 7:25 a.m. pending the FDA's news. This incident is isolated from broader market trends, with major indices like the S&P 500, Dow Jones, and Nasdaq all up today. The combination of the FDA's partial hold and the lingering uncertainty about its potential lifting significantly increased the perceived risk in Bright Minds' pipeline, pushing DRUG to a 52-week low of $23.00 during the session.